Cytostatic hypothermia and its impact on glioblastoma and survival.

Autor: Enam SF; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA.; Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA., Kilic CY; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Huang J; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Kang BJ; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Chen R; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Tribble CS; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Ilich E; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Betancur MI; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Blocker SJ; Department of Radiology, Center for In Vivo Microscopy, Duke University, Durham, NC 27705, USA., Owen SJ; Bio-medical Machine Shop, Pratt School of Engineering, Duke University, Durham, NC 27705, USA., Buckley AF; Department of Pathology, School of Medicine, Duke University, Durham, NC 27705, USA., Lyon JG; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA.; Department of Biology, Emory University, Atlanta, GA 30332, USA., Bellamkonda RV; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27705, USA.; Department of Biology, Emory University, Atlanta, GA 30332, USA.
Jazyk: angličtina
Zdroj: Science advances [Sci Adv] 2022 Nov 25; Vol. 8 (47), pp. eabq4882. Date of Electronic Publication: 2022 Nov 25.
DOI: 10.1126/sciadv.abq4882
Abstrakt: Patients with glioblastoma (GBM) have limited options and require novel approaches to treatment. Here, we studied and deployed nonfreezing "cytostatic" hypothermia to stunt GBM growth. This growth-halting method contrasts with ablative, cryogenic hypothermia that kills both neoplastic and infiltrated healthy tissue. We investigated degrees of hypothermia in vitro and identified a cytostatic window of 20° to 25°C. For some lines, 18 hours/day of cytostatic hypothermia was sufficient to halt division in vitro. Next, we fabricated an experimental tool to test local cytostatic hypothermia in two rodent GBM models. Hypothermia more than doubled median survival, and all rats that successfully received cytostatic hypothermia survived their study period. Unlike targeted therapeutics that are successful in preclinical models but fail in clinical trials, cytostatic hypothermia leverages fundamental physics that influences biology broadly. It is a previously unexplored approach that could provide an additional option to patients with GBM by halting tumor growth.
Databáze: MEDLINE